Arena Pharma (ARNA) PT Raised to $63 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Arena Pharma (ARNA) PT Raised to $63 at Credit Suisse
February 27, 2019 8:02 AM ESTCredit Suisse analyst Martin Auster raised the price target on Arena Pharma (NASDAQ: ARNA) to $63.00 (from $61.00) while maintaining a Outperform rating.
... MoreArena Pharma (ARNA) PT Raised to $79 at RBC Capital
February 27, 2019 6:43 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Arena Pharma (NASDAQ: ARNA) to $79.00 (from $70.00) while maintaining a Outperform rating.
Flush with cash, ARNA positions to execute in the clinic in 2019, MacKay comments.
... More